U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22O8
Molecular Weight 414.4061
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PODOFILOX

SMILES

COc1cc(cc(c1OC)OC)[C@]2([H])c3cc4c(cc3[C@@]([H])([C@@]5([H])COC(=O)[C@@]52[H])O)OCO4

InChI

InChIKey=YJGVMLPVUAXIQN-XVVDYKMHSA-N
InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/?term=9562603 http://products.sanofi.ca/en/condyline.pdf

Podofilox ((abbreviated as PPT), otherwise known as podofilox) is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Podofilox 0.5% solution is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts. Treatment of genital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown, but is believed to exert its antimitotic effect by binding to tubulin, at a site close to but not identical to the binding site of colchicine; it is thought that this antimitotic effect causes necrosis of wart tissue, the observed clinical effect. In addition, podofilox is known to interfere with nucleoside transport, which may also contribute to its action. Adverse effects reported in less than 5% of the patients included pain with intercourse, insomnia, tingling, bleeding, tenderness, chafing, malodor, dizziness, scarring, vesicle formation, crusting edema, dryness/peeling, foreskin irretraction, hematuria, vomiting and ulceration.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2095182
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CONDYLOX

Approved Use

Podofilox Topical Solution 0.5% is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts (see PRECAUTIONS ). Diagnosis Although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma (so-called Bowenoid papulosis) is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with Podofilox Topical Solution 0.5%.

Launch Date

6.6104643E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17 ng/mL
1.5 mL single, topical
dose: 1.5 mL
route of administration: Topical
experiment type: SINGLE
co-administered:
PODOFILOX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.5 h
1.5 mL single, topical
dose: 1.5 mL
route of administration: Topical
experiment type: SINGLE
co-administered:
PODOFILOX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (79.2%)
Pain (79.2%)
Itching (83.3%)
Bleeding (45.8%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (49.4%)
Pain (54.3%)
Itching (59.3%)
Bleeding (29.6%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (52.3%)
Pain (55.8%)
Itching (60.5%)
Bleeding (32.6%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (83.2%)
Pain (49.6%)
Itching (52.9%)
Bleeding (28.6%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (81.9%)
Pain (50.4%)
Itching (52.8%)
Bleeding (26.8%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (71.4%)
Pain (71.4%)
Itching (57.1%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (mild, 32.2%)
Pain (mild, 23.7%)
Itching (mild, 32.2%)
Bleeding (mild, 19.2%)
Inflammation (moderate, 30.4%)
Pain (moderate, 20.4%)
Itching (moderate, 16%)
Bleeding (moderate, 3%)
Inflammation (severe, 9.3%)
Pain (severe, 11.5%)
Itching (severe, 7.8%)
Bleeding (severe, 0.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Bleeding 45.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
Inflammation 79.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
Pain 79.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
Itching 83.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
Bleeding 29.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
Inflammation 49.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
Pain 54.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
Itching 59.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
Bleeding 32.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
Inflammation 52.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
Pain 55.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
Itching 60.5%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
Bleeding 28.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
Pain 49.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
Itching 52.9%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
Inflammation 83.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
Bleeding 26.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
Pain 50.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
Itching 52.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
Inflammation 81.9%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
Itching 57.1%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
Inflammation 71.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
Pain 71.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
Bleeding mild, 19.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Pain mild, 23.7%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Inflammation mild, 32.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Itching mild, 32.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Itching moderate, 16%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Pain moderate, 20.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Bleeding moderate, 3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Inflammation moderate, 30.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Bleeding severe, 0.7%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Pain severe, 11.5%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Itching severe, 7.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Inflammation severe, 9.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Sensory neuropathy due to Bajiaolian (Podophyllotoxin) intoxication.
2000
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Enhanced podophyllotoxin production from Agrobacterium rhizogenes transformed cultures of Podophyllum hexandrum.
2001
Issues and practicalities of treating genital warts in the community. Proceedings of a round table meeting facilitated by Succinct Communications Limited.
2001
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
2001 Apr
A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.
2001 Apr 20
Secoisolariciresinol dehydrogenase purification, cloning, and functional expression. Implications for human health protection.
2001 Apr 20
The successful treatment of molluscum contagiosum with podophyllotoxin (0.5%) self-application.
2001 Dec
A fast and simple GC MS method for lignan profiling in Anthriscus sylvestris and biosynthetically related Plant species.
2001 Dec
Podophyllin office therapy against condyloma should be abandoned.
2001 Dec
High yield of podophyllotoxin from leaves of Podophyllum peltatum by in situ conversion of podophyllotoxin 4- O-beta-D-glucopyranoside.
2001 Feb
[Clinical aspects and therapy of anogenital warts and papillomavirus-associated lesions].
2001 Jan
GATA-4 and serum response factor regulate transcription of the muscle-specific carnitine palmitoyltransferase I beta in rat heart.
2001 Jan 12
Cytotoxic responses to aromatic ring and configurational variations in alpha-conidendrin, podophyllotoxin, and sikkimotoxin derivatives.
2001 Jan 18
[PAPP-A in the first trimester of pregnancy].
2001 Jul
TNF-alpha downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding.
2001 Jun
The production of cytotoxic lignans by plant cell cultures.
2001 Mar
Direct medical costs for surgical and medical treatment of condylomata acuminata.
2001 Mar
Contact dermatitis from topical antiviral drugs.
2001 May
A pancreatic beta -cell-specific enhancer in the human PDX-1 gene is regulated by hepatocyte nuclear factor 3beta (HNF-3beta ), HNF-1alpha, and SPs transcription factors.
2001 May 18
Analytical approaches for traditional chinese medicines exhibiting antineoplastic activity.
2001 Nov 25
Management of anogenital warts (condylomata acuminata).
2001 Nov-Dec
Second malignancy after treatment of childhood non-Hodgkin lymphoma.
2001 Oct 1
[Myelotoxicity of a plant cytostatic preparation etoposide].
2001 Sep-Oct
Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream.
2001 Sep-Oct
Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia.
2002
Clinical inquiries. What is the most effective treatment for external genital warts?
2002 Apr
Antitumor and antioxidant activity of spin labeled derivatives of podophyllotoxin (GP-1) and congeners.
2002 Apr 5
Biological activity of 4-acetyltropolone, the minor component of Thujopsis dolabrata SIeb. et Zucc. hondai Mak.
2002 Aug
[Incidence and management of condylomata acuminata by French general physicians].
2002 Aug-Sep
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
2002 Dec 15
Prodrugs of 4'-demethyl-4-deoxypodophyllotoxin: synthesis and evaluation of the antitumor activity.
2002 Dec 2
Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness.
2002 Feb 15
Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells.
2002 Jul-Aug
Flow cytometric estimation on cytotoxic activity of leaf extracts from seashore plants in subtropical Japan: isolation, quantification and cytotoxic action of (-)-deoxypodophyllotoxin.
2002 Jun
Methamphetamine activates DNA binding of specific redox-responsive transcription factors in mouse brain.
2002 Oct 1
A multicomponent reaction for the one-pot synthesis of 4-aza-2,3-didehydropodophyllotoxin and derivatives.
2002 Sep 19
Synthesis and cytotoxicity of podophyllotoxin analogues modified in the A ring.
2003 Jan
[Bacteremia due to Capnocytophaga spp.: two cases].
2003 Mar
Patents

Sample Use Guides

Apply twice daily morning and evening (every 12 hours), for 3 consecutive days, then withhold use for 4 consecutive days. This 1 week cycle of treatment may be repeated up to four times until there is no visible wart tissue. Podofilox 0.5% solution is applied to the warts with a cotton-tipped applicator supplied with the drug. The drug-dampened applicator should be touched to the wart to be treated, applying the minimum amount of solution necessary to cover the lesion. Treatment should be limited to less than 10 cm2 of wart tissue and to no more than 0.5 mL of the solution per day.
Route of Administration: Vaginal
In Vitro Use Guide
Unknown
Name Type Language
PODOFILOX
HSDB   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
PODOPHYLLOTOXIN [EP MONOGRAPH]
Common Name English
NSC-24818
Code English
PODOFILOX [VANDF]
Common Name English
PODOPHYLLOTOXIN
MART.   MI   WHO-DD  
Common Name English
PODOFILOX [ORANGE BOOK]
Common Name English
PODOPHYLLOTOXIN [MI]
Common Name English
PODOPHYLLOTOXIN [WHO-DD]
Common Name English
PODOPHYLLOTOXIN [MART.]
Common Name English
CONDYLOX
Brand Name English
PODOFILOX [HSDB]
Common Name English
FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE, 5,8,8A,9-TETRAHYDRO-9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-, (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.ALPHA.))-
Common Name English
(5R,5AR,8AR,9R)-5,8,8A,9-TETRAHYDRO-9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE
Common Name English
PODOFILOX [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000008732
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
NCI_THESAURUS C67421
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
WHO-ATC D06BB04
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
WHO-VATC QD06BB04
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
Code System Code Type Description
PUBCHEM
10607
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
HSDB
7238
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
EVMPD
SUB14925MIG
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
RXCUI
8463
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M8933
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL61
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
CAS
518-28-5
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
FDA UNII
L36H50F353
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
NCI_THESAURUS
C29368
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
WIKIPEDIA
PODOPHYLLOTOXIN
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
DRUG CENTRAL
3481
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
MESH
D011034
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
ECHA (EC/EINECS)
208-250-4
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
EPA CompTox
518-28-5
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
DRUG BANK
DB01179
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY